论文部分内容阅读
近几年关于抗肿瘤血管生成药物的研究越来越多,血管内皮生长因子受体(vascular endothelial growth factor receptors,VEGFR)在血管形成过程起重要作用。阿帕替尼是一种新型口服小分子VEGFR酪氨酸激酶抑制剂(tyrosine kinase inhibitors,TKI),目前主要用于晚期胃癌、乳腺癌和肺癌等治疗,目前已进入Ⅲ期临床试验。相比于同类药物索拉非尼和舒尼替尼,阿帕替尼显现出更高的体外和体内活性,具有很强的抗肿瘤作用。本文就关于阿帕替尼的研究背景、临床研究和药物不良反应进行综述。
In recent years, there are more and more researches on antitumor angiogenesis drugs. The vascular endothelial growth factor receptors (VEGFRs) play an important role in the process of angiogenesis. Apatinib is a novel oral small molecule VEGFR tyrosine kinase inhibitor (TKI), currently used mainly for advanced gastric cancer, breast cancer and lung cancer treatment, has entered the phase Ⅲ clinical trial. Compared with similar drugs sorafenib and sunitinib, apatinib showed higher in vitro and in vivo activity, has a strong anti-tumor effect. This article reviews the research background, clinical studies and adverse drug reactions of apatinib.